European regulation on orphan medicinal products: 10 years of experience and future perspectives

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A10293954" target="_blank" >RIV/00064203:_____/11:10293954 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:10293954

Výsledek na webu

<a href="http://dx.doi.org/10.1038/nrd3445" target="_blank" >http://dx.doi.org/10.1038/nrd3445</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/nrd3445" target="_blank" >10.1038/nrd3445</a>

Jazyk výsledku

angličtina

Název v původním jazyce

European regulation on orphan medicinal products: 10 years of experience and future perspectives

Popis výsledku v původním jazyce

In 2000, regulation on orphan medicinal products was adopted in the European Union with the aim of benefiting patients who suffer from serious, rare conditions for which there is currently no satisfactory treatment. Since then, more than 850 orphan drugdesignations have been granted by the European Commission based on a positive opinion from the Committee for Orphan Medicinal Products (COMP), and more than 60 orphan drugs have received marketing authorization in Europe. Here, stimulated by the tenth anniversary of the COMP, we reflect on the outcomes and experience gained in the past decade, and contemplate issues for the future, such as catalysing drug development for the large number of rare diseases that still lack effective treatments.

Název v anglickém jazyce

European regulation on orphan medicinal products: 10 years of experience and future perspectives

Popis výsledku anglicky

In 2000, regulation on orphan medicinal products was adopted in the European Union with the aim of benefiting patients who suffer from serious, rare conditions for which there is currently no satisfactory treatment. Since then, more than 850 orphan drugdesignations have been granted by the European Commission based on a positive opinion from the Committee for Orphan Medicinal Products (COMP), and more than 60 orphan drugs have received marketing authorization in Europe. Here, stimulated by the tenth anniversary of the COMP, we reflect on the outcomes and experience gained in the past decade, and contemplate issues for the future, such as catalysing drug development for the large number of rare diseases that still lack effective treatments.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nature Reviews Drug Discovery

ISSN

1474-1776

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

341-349

Kód UT WoS článku

000290017300016

EID výsledku v databázi Scopus

—